REDICA Systems

A Deeper Dive into FDA's Newly Published Complete Response Letters (CRLs)

In 2025, the FDA took a significant step toward greater transparency by publishing, for the first time, a centralized database of Complete Response Letters (CRLs). This marks a notable shift in how regulatory information is shared, offering unprecedented visibility into the reasons why applications are not approved.

While this initiative improves accessibility and convenience, it does not make all of this information entirely new. Many of the CRLs now consolidated in the FDA database were already publicly available within the approval packages of approved products, if one knew where to look. The true innovation lies in the ease of discovery; for the first time, industry stakeholders can access hundreds of CRLs in a single, centralized source.

Importantly, the FDA also released a subset of CRLs tied to unapproved or withdrawn applications, which had not been previously published since those products lack approval packages. However, these CRLs are much more heavily redacted, often obscuring key contextual details such as facility inspection information or specific deficiency narratives.

Building on this new transparency, Redica Systems went a step further. Our team ingested, labeled, and analyzed the newly released CRL data, but we didn't stop there. We supplemented the agency's database with additional CRL events identified through other public sources, including approval packages, press releases, and industry news. (**See Figure 1**)

By linking this expanded dataset to inspection records, Form 483s, and site compliance histories, Redica transformed a static collection of documents and events into a comprehensive, searchable, and analyzable dataset that reveals trends, correlations, and risk factors.

This deeper analysis converts accessibility and transparency into actionable intelligence, helping life sciences organizations move beyond awareness to understanding - uncovering the patterns, root causes, and risk factors that drive CRL outcomes and inform stronger regulatory strategies.

WHY IT MATTERS

(**See Figure 2**)

- More than half (53%) of all NDAs/BLAs receive a Complete Response Letter.
- 41% of CRLs are driven by GMP deficiencies discovered during pre-approval inspections.
- For companies utilizing shared CMO/CDMO facilities, the risk is even higher - one site can jeopardize multiple submissions.
- Redica's data shows approximately a 22% likelihood of receiving a CRL due to GMP-related issues.

The message is clear: early visibility into site and inspection risk factors can prevent costly approval delays.



FIGURE 1 | REDICA CRL DATABASE 2022 - 2025

NDA/ BLAs leading to CRLs

	2022	2023	2024	2025 (Q1 - Q3)
NDA / BLA PDUFAs	92	121	133	92
NDA / BLA CRLs	41 (45%)	60 (50%)	90 (68%)	43 (47%)
NDA / BLA GMP CRLs	18 (44%)	21 (35%)	39 (43%)	19 (44%)

FIGURE 2 | NDA/BLAS LEADING TO CRLS

METHODOLOGY - LINKING CRLS TO INSPECTIONS

STEP 1: IDENTIFYING GMP-RELATED CRLS

Redica's analysts identified 234 CRL events from 2022 through Q3 2025 by combining FDA disclosures, approval package data, and public announcements. When categorized by primary deficiency type, Product Quality issues accounted for the largest share—representing roughly 50–60% of all CRLs across this period. Clinical deficiencies followed at about 20–40%, with smaller proportions attributed to Safety (~4–8%) and Other administrative causes (~4–7%).

Among **147 product quality related CRLs, 97 were classified as GMP-related**, representing instances where deficiencies observed during a Pre-Approval or Pre-License Inspection (PAI/PLI) directly contributed to the FDA's decision to issue a CRL. This subset reveals a growing intersection between manufacturing readiness and approval outcomes. Interestingly, three of these GMP CRLs stemmed from cases where the FDA could not complete the inspection because "the facility was not ready for inspection."

The year-over-year trend suggests a steady increase in manufacturing-related CRLs from 2022 through 2024, peaking with **62 CRLs linked to product quality in 2024**, indicating that manufacturing controls, sterility assurance, and microbiological robustness continue to be key determinants of pre-approval success.



FIGURE 3 | 234 CRL EVENTS IDENDIFIED BY REDICA SYSTEMS 2022 - 2025

STEP 2: MAPPING PRE-APPROVAL INSPECTIONS (PAIS)

To understand inspection patterns behind CRLs, Redica examined all human drug and biologic GMP inspections since 2022, excluding surveillance and for-cause inspections, and generic product categories.

The resulting dataset included **499 pre-approval inspections (PAIs) potentially linked to CRL events.**



FIGURE 4 | FDA GMP INSPECTIONS WATERFALL 2022 - Q3 2025

STEP 3: LINKING CRLS TO PAIS

The final step involved linking GMP CRL events to specific pre-approval inspections using multiple data sources - site identifying information listed in the complete response or approval package, manufacturer listings on drug labels, and proprietary Redica linkages.

Through this intensive data integration, Redica successfully matched 32 CRLs to specific PAIs - a first-of-its-kind linkage analysis in the industry.

These matched cases became the foundation for deeper inspection analytics, enabling the identification of key CRL risk factors.



FIGURE 5 | SOURCES FOR PAI LINKAGE

PATTERNS IN CRL-LINKED INSPECTIONS

Across the 32 linked inspections, Redica observed several recurring characteristics:

- Facilities with **poor or very poor compliance scores**
- **CMO/CDMO** manufacturing sites, particularly those handling **parenteral products**
- **For-cause inspections** or those conducted by **multiple investigators**
- Inspectors with histories of multiple CRL-linked findings
- Inspections resulting in **Official Action Indicated (OAI)** or **Warning Letter (WL) outcomes**
- Form 483s containing **five or more observations or multiple major/critical findings**

These indicators collectively contribute to a higher likelihood of a Complete Response Letter.

483 CLUSTER ANALYSIS: CMO VS. SPONSOR TRENDS

Redica AI analyzed **25 Form 483s** associated with CRL-linked inspections—**14 from CMOs** (62 observations) and **11 from Sponsors** (66 observations)—to uncover the most frequent and severe GMP issues.

DEFICIENCY CLUSTERS:



FIGURE 6 | CMO INSPECTIONS



FIGURE 7 | SPONSOR INSPECTIONS

DIFFERENCES BETWEEN CMOS AND SPONSORS

While both CMOs and Sponsors shared recurring issues in contamination control, data integrity, and training oversight, their primary risk areas differed. CMOs were more prone to equipment and facility maintenance gaps, Quality Unit oversight failures, and weaknesses in smoke studies and airflow visualization. Sponsors, on the other hand, more often faced process control and validation failures, aseptic processing validation issues, and inadequate SOPs and procedures. These patterns suggest that CMOs tend to struggle with infrastructure and oversight challenges, whereas Sponsors face greater risks in procedural execution and process validation.

CRL RISK MODEL

Building on this foundation, Redica Systems developed a multifactorial CRL Risk Model that integrates inspection metadata, Form 483 analytics, and historical site compliance data.

The model assigns weighted scores across several dimensions:

- Facility profile (type, Redica Site Score)
- Inspection characteristics (for-cause, NDA/BLA, parenteral)
- Investigator history (number of CRL-linked inspections)
- Document signals (483 observations, severity levels)
- Enforcement outcomes (WL/OAI)

When applied to recent pre-approval inspections, the model accurately identifies high-risk inspections, even when no CRL has yet been issued, helping sponsors and manufacturers proactively mitigate risk.



FIGURE 8 | REDICA SYSTEMS PLATFORM

LOOKING AHEAD

The FDA's move toward public CRL data marks only the beginning of a new era in regulatory transparency. As the agency continues to expand CRL disclosures, Redica Systems will refine and expand its analytics to include:

- Continuous integration of newly released CRLs
- Deeper linkage between PAIs, 483s, and enforcement outcomes
- Predictive tools embedded within Redica Platform inspection profiles

By empowering sponsors with these insights, Redica enables smarter decision-making, improved inspection readiness, and ultimately, faster approvals.

ACCESS THE FULL DATASET

Interested in exploring Redica's CRL analytics or requesting a list of linked PAIs / PLIs and high-risk inspections? Request a demo today!

ABOUT REDICA SYSTEMS

Redica Systems delivers actionable intelligence that helps life sciences organizations strengthen compliance and accelerate product approvals. By transforming complex regulatory data into actionable insights, Redica empowers teams to anticipate risk, prepare for inspections, and uphold the highest standards of quality and patient safety.